Rutin-Doped Hybrid Nanoparticles: Effect of the Molecular Doping Density on T 1 Relaxivity and Their Application in Targeted Magnetic Resonance Imaging of Malignant Tumors
Nano Letters · 29.07.2026 · 26 (29) · 9561-9569
DOI: 10.1021/acs.nanolett.6c02191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, online erschienen am 14.07.2026. Verfasst von Shengxiang Fu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang212001, China. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Rutin, Contrast Media, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Natural Science Foundation of Sichuan Province, National Natural Science Foundation of China (NSFC), Social Development Foundation of Jiangsu Province.
Abstract (Originalsprache)
Molecular doping is a promising strategy to tune the performance such as relaxivity and targeting ability of magnetic resonance imaging (MRI) nanocontrast agents. Herein, hybrid nanoparticles of amphiphilic manganese complex (MnL) and DSPE-PEG were first prepared, and it was found that a higher DSPE-PEG doping density reduced size and increased T1 relaxivity. Then, rutin (Ru) doping further transformed hybrid nanoparticle morphology from spherical to snowflake-like, decreased size, and enhanced T1 relaxivity by increasing the number of coordinated water molecules (q) and water exchange rate (1/τM). Ru-doped hybrid nanoparticles (MnL/Ru NP5) with a MnL/DSPE-PEG/Ru mass ratio of 1/2/4 exhibited the highest T1 relaxivity and good stability and biosafety and were selected for in vivo tumor-targeted MRI. MnL/Ru NP5 shows promise for MRI of H22 tumors thanks to its effective glucose transporters (GLUTs)-mediated tumor-cell-targeting ability. Our molecular doping strategy provides a potential way for the structural design of high-performance hybrid nanocontrast agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang212001, China.
- Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, West China Hospital, Sichuan University, Chengdu610041, China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing400016, China.
- National Engineering Research Center for Biomaterials and College of Biomedical Engineering, Sichuan University, Chengdu610065, China.
ORCID-Profile: Shengxiang Fu, Zhongyuan Cai, Haojie Gu, Hsiang-I Tsai, Haitao Zhu
Förderung
- Natural Science Foundation of Sichuan Province
- National Natural Science Foundation of China (NSFC)
- Social Development Foundation of Jiangsu Province
- Jiangsu Province Natural Science Foundation for Excellent Young Scholars
Zitieren
APA
Fu, S., Wang, X., Cai, Z., Liu, L., Gu, H., Tsai, H. I., Wang, D., Ai, H., & Zhu, H. (2026). Rutin-Doped Hybrid Nanoparticles: Effect of the Molecular Doping Density on T 1 Relaxivity and Their Application in Targeted Magnetic Resonance Imaging of Malignant Tumors. Nano Letters, 26(29), 9561-9569. https://doi.org/10.1021/acs.nanolett.6c02191
Vancouver
Fu S, Wang X, Cai Z, Liu L, Gu H, Tsai HI, et al. Rutin-Doped Hybrid Nanoparticles: Effect of the Molecular Doping Density on T 1 Relaxivity and Their Application in Targeted Magnetic Resonance Imaging of Malignant Tumors. Nano Letters. 2026;26(29):9561-9569. doi:10.1021/acs.nanolett.6c02191
BibTeX
@article{Fu2026,
author = {Fu, Shengxiang and Wang, Xin and Cai, Zhongyuan and Liu, Li and Gu, Haojie and Tsai, Hsiang-I and Wang, Dongqing and Ai, Hua and Zhu, Haitao},
title = {Rutin-Doped Hybrid Nanoparticles: Effect of the Molecular Doping Density on T 1 Relaxivity and Their Application in Targeted Magnetic Resonance Imaging of Malignant Tumors},
journal = {Nano Letters},
year = {2026},
volume = {26},
number = {29},
pages = {9561--9569},
doi = {10.1021/acs.nanolett.6c02191}
}
EUVIMED